07:00 , Sep 7, 2015 |  BC Week In Review  |  Company News

RESprotect, RedHill deal

RedHill elected to extend by one year an August 2014 deal granting it a one-year option to license exclusive, worldwide rights to RESprotect’s RP101 for all indications. The deal excludes rights in South Korea...
07:00 , Aug 3, 2015 |  BC Week In Review  |  Company News

Broda Tech, Redwood Pharma deal

Broda granted Redwood exclusive, worldwide rights to use IntelliGel supramolecular hydrogel technology for ophthalmic indications. Redwood has reformulated its RP101 -- a daily topical eye treatment based on a naturally occurring endogenous molecule --...
07:00 , Sep 8, 2014 |  BC Week In Review  |  Company News

RESprotect, RedHill deal

RedHill received a one-year option from RESprotect to acquire exclusive, worldwide rights to RP101 for all indications, excluding pancreatic cancer in South Korea. RedHill may conduct development of the compound during the option period,...
07:00 , Jul 4, 2011 |  BC Week In Review  |  Company News

SciClone, RESprotect deal

RESprotect said SciClone returned North American rights to pancreatic cancer candidate RP101. SciClone discontinued a Phase II trial of the small molecule that binds to heat shock protein 27 (Hsp27) in 2009 based...
08:00 , Jan 4, 2010 |  BioCentury  |  Finance

Restructuring watch

Restructuring watch Date Company Staff cuts Cash Years cash pre-cut Cash date Oper loss for 9 mos ended 9/30 10/28/09 SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) 17% to...
08:00 , Nov 16, 2009 |  BC Week In Review  |  Clinical News

Brivudine regulatory update

EMEA's Committee for Orphan Medicinal Products (COMP) issued a positive opinion to grant Orphan Drug designation for RESprotect's RP101 to treat pancreatic cancer. The small molecule that binds to heat shock protein 27 (Hsp27)...
08:00 , Nov 2, 2009 |  BC Week In Review  |  Company News

SciClone cancer news

SciClone will restructure and reduce headcount by seven (17%) to 34, with cuts primarily in research and development. In October, SciClone discontinued a Phase II of RP101 to treat advanced pancreatic cancer based on the...
07:00 , Oct 12, 2009 |  BC Week In Review  |  Clinical News

BvdU: Phase II discontinued

SciClone discontinued a double-blind, placebo-controlled Phase II trial based on the recommendation of an independent DSMC. The company said it is "disappointed with the discontinuation of this study" and it will provide further details when...
07:00 , Oct 12, 2009 |  BioCentury  |  Finance

Ebb & Flow

Facet Biotech Corp. (NASDAQ:FACT) executives seem confident that investors aren't going to take the bait on the $14.50 per share tender offer from Biogen Idec Inc. (NASDAQ:BIIB) - and they cite the company's stock price...
01:32 , Oct 6, 2009 |  BC Extra  |  Financial News

SciClone discontinues pancreatic cancer trial

SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) fell $0.42 (10%) to $3.73 on Monday after discontinuing a Phase II trial of RP101 (BvdU) to treat advanced pancreatic cancer based on the recommendation of an independent DSMC. The company...